The treatment of multiple myeloma has changed dramatically over the past 15 years. Patients are living longer. In patients who are newly diagnosed, triple therapy has resulted in high response rates and deeper, longer lasting responses. However, due to the heterogeneous nature of the disease, treating at relapse is still a challenge. Further complicating the decision making process is the number of new therapies approved over the past few years.
A new article published today published in Cancer Therapy Advisor, Dr. Joseph Mikhael discusses the challenge of selecting the appropriate treatment for patients with relapsed multiple myeloma.